Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) (SGN + Benda) (NCT01657331)
This is a Phase I/II multicenter study to assess the safety and effectiveness of brentuximab vedotin (also known as SGN-035) and bendamustine, when given together, in patients with Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma (ALCL) that has either returned or did not respond to initial treatment(s). Patients will be accrued at Columbia University Medical Center (CUMC) and at two subsites in Canada.
In this trial, brentuximab vedotin will be given to patients on day 1 of each 21 day cycle and bendamustine will be given to patients on days 1 AND 2 of each 21 day cycle. Days 3-21 will be for rest.
This trial is sponsored by Owen A. O’Connor/Columbia University. 
- Condition: Lymphoma
- Phase: I & II
- Estimated Enrollment: 71
- Start: July 2012
- Estimated Completion: August 2015
- Last verified: January 2015
Last Editorial review: July 6, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.